Publications by authors named "R Porrini"
Article Synopsis
- - Deferasirox (DFX) is used to treat iron overload in myelofibrosis (MF) patients receiving ruxolitinib (RUX), and a study evaluated the safety and efficacy of the RUX-DFX combination in 69 MF patients.
- - Results showed that 47.8% of patients achieved iron chelation response (ICR) and 46.4% had an erythroid response (ER), with 18.9% becoming transfusion-independent; no unexpected toxicities were reported.
- - Factors predicting improved survival included the absence of leukocytosis and achieving ICR, indicating that the RUX-DFX regimen may benefit MF patients and warrants further research.
Background And Aims: Anagrelide is a drug effective in reducing platelet counts in essential thrombocythemia (ET) and Ph1-negative myeloproliferative neoplasms. The aim of this study was to evaluate the real-life use of anagrelide in patients with ET followed over 25 years at the Haematological Institutes belonging to "Ph1-negative Myeloproliferative Neoplasms Latium Group."
Patients And Methods: Eligibility criteria were diagnosis of ET and treatment with anagrelide.
Background And Objectives: While tyrosine kinase inhibitors (TKIs) have transformed CP-CML management, limited data exist on their use in clinical practice.
Methods: SIMPLICITY (NCT01244750) is an observational study in CP-CML patients, exploring first-line (1L) TKI use and management patterns in the US and Europe. Over half of the patients recruited in Europe are from Italy (n=266).
Background: Currently, there are no data available on the best choice of treatment in heavily pretreated patients with advanced breast cancer. However, the combination of oral vinorelbine and capecitabine has been demonstrated to be effective and safe in patients with advanced breast cancer pretreated with anthracycline. Furthermore, some studies assessed the activity of dasatinib, an oral tyrosine kinase inhibitor that inhibits five oncogenic tyrosine kinase families, alone or in combination with different chemotherapy in patients affected with advanced breast cancer.
View Article and Find Full Text PDF